Evidence map›Paper›PMID 42806686›Full record

ArticleBiometrical journal. Biometrische Zeitschrift2026

Optimal Designs for Identifying Effective Doses in Drug Combination Studies.

Leonie Schürmeyer, Ludger Sandig, Jorrit Kühne, Leonie T Hezler, Bernd-Wolfgang Igl, Kirsten Schorning

Abstract read
In one paragraph

Article in Biometrical journal. Biometrische Zeitschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Optimal Designs for Identifying Effective Doses in Drug Combination Studies.Biometrical journal. Biometrische Zeitschrift · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leonie SchürmeyerDepartment of Statistics, TU Dortmund University, Dortmund, North Rhine-Westphalia, Germany.ORCID https://orcid.org/0000-0001-9811-3641
Ludger SandigDepartment of Statistics, TU Dortmund University, Dortmund, North Rhine-Westphalia, Germany.
Jorrit KühneDepartment of Statistics, TU Dortmund University, Dortmund, North Rhine-Westphalia, Germany.
Leonie T HezlerGlobal Experimental Medicine, Data and Analytics, Boehringer Ingelheim Pharma GmbH & Co. KG, Baden-Wuerttemberg, Germany.
Bernd-Wolfgang IglGlobal Experimental Medicine, Data and Analytics, Boehringer Ingelheim Pharma GmbH & Co. KG, Baden-Wuerttemberg, Germany.
Kirsten SchorningDepartment of Statistics, TU Dortmund University, Dortmund, North Rhine-Westphalia, Germany.

Funding

Deutsche Forschungsgemeinschaft 427806116
6 · The paper itself

Abstract

We consider the optimal design problem for identifying effective dose combinations within drug combination studies where the effect of the combination of two drugs is investigated. Drug combination studies are becoming increasingly important as they investigate potential interaction effects rather than the individual impacts of the drugs. In this situation, identifying effective dose combinations that yield a prespecified effect is of special interest. If nonlinear surface models are used to describe the dose combination-response relationship, these effective dose combinations, also called isoboles, result in specific contour lines of the fitted response model. Consequently, accurately estimating these effective dose combinations is crucial. We propose a novel design criterion that targets the precise estimation of these effective dose combinations. In particular, an optimal design minimizes the width of the confidence band of the contour lines of interest. Optimal design theory is developed for this problem, including equivalence theorems and efficiency bounds. The performance of the optimal design is illustrated in different examples modeling dose combination data by various nonlinear surface models. It is demonstrated that the proposed optimal design for identifying effective dose combinations yields a more precise estimation of the effective dose combinations than ray or factorial designs, which are commonly used in practice. This particularly holds true for a case study motivated by data from an oncological dose combination study.

Indexed as

BiometryDose-Response Relationship, DrugHumansModels, StatisticalNonlinear Dynamics

Identifiers

PMID42806686
PMCPMC13620475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.